Pijl S
Division of Otolaryngology, St. Paul's Hospital, Vancouver, British Columbia.
J Otolaryngol. 1994 Aug;23(4):286-91.
Seven Nucleus, multichannel, cochlear-implant recipients underwent a 4-week trial with a Research Speech Processor (RSP). For five users of the Wearable Speech Processor (WSPIII), the RSP consisted of a Mini Speech Processor (MSP) with a MultiPeak (MPEAK) coding strategy, and for two MSP users, a WSPIII, utilizing an F0F1F2 coding strategy was used. Scores on an auditory-only, speech perception test battery were used to compare performance with each device. Patients were evaluated with their own processor before and after their RSP experience, to assess potential practice effects. In general, the patients with higher baseline scores appeared to be better able to take advantage of the additional information provided by the MSP/MPEAK combination.
七名接受多通道人工耳蜗植入的患者使用研究型言语处理器（RSP）进行了为期4周的试验。对于五名可穿戴式言语处理器（WSPIII）的使用者，RSP由带有多峰（MPEAK）编码策略的迷你言语处理器（MSP）组成；对于两名MSP使用者，则使用采用F0F1F2编码策略的WSPIII。仅基于听觉的言语感知测试组的分数用于比较每个设备的性能。在使用RSP前后，对患者使用其自己的处理器进行评估，以评估潜在的练习效果。总体而言，基线分数较高的患者似乎更能利用MSP/MPEAK组合提供的额外信息。
